Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus: Discordance Between ELISA and Proximity Extension Assay

Insa M. Schmidt; Mia R. Colona; Anand Srivastava; Guanghao Yu; Venkata Sabbisetti; Joseph V. Bonventre; Sushrut S. Waikar

doi:10.1016/j.xkme.2022.100496

Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus: Discordance Between ELISA and Proximity Extension Assay

Insa M. Schmidt^*, Mia R. Colona, Anand Srivastava, Guanghao Yu, Venkata Sabbisetti, Joseph V. Bonventre, Sushrut S. Waikar

^*Corresponding author for this work

Medicine, Nephrology Division

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Article number	100496
Journal	Kidney Medicine
Volume	4
Issue number	8
DOIs	https://doi.org/10.1016/j.xkme.2022.100496
State	Published - Aug 2022

Keywords

ELISA
Olink
plasma kidney injury molecule-1
proteomics

ASJC Scopus subject areas

Nephrology
Internal Medicine

Access to Document

10.1016/j.xkme.2022.100496

Cite this

@article{5493af61c7e44a7e9edd3a77a557c0d2,

title = "Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus: Discordance Between ELISA and Proximity Extension Assay",

keywords = "ELISA, Olink, plasma kidney injury molecule-1, proteomics",

author = "Schmidt, {Insa M.} and Colona, {Mia R.} and Anand Srivastava and Guanghao Yu and Venkata Sabbisetti and Bonventre, {Joseph V.} and Waikar, {Sushrut S.}",

note = "Funding Information: Research idea and study design: IMS, SSW; data acquisition: MRC, VS, AS, SSW; data analysis/interpretation: IMS, AS, GY, JVB, SSW; statistical analysis: IMS; supervision or mentorship: SSW, JVB. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Funding for the Boston Kidney Biopsy Cohort was provided by the National Institutes of Health (NIH) grant R01DK093574 (Dr Waikar). Dr Schmidt is supported by the American Philosophical Society Daland Fellowship in Clinical Investigation. Dr Srivastava is supported by NIH grant K23DK120811, National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Precision Medicine Project Opportunity Pool grant under U2CDK114886, and core resources from the George M. O'Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Waikar is also supported by NIH grants UH3DK114915, U01DK085660, U01DK104308, R01DK103784, R01DK093574, and R21DK119751. Dr Bonventre is supported by grants U01DK085660, R01DK072381, and R37DK39773. None of the funders of this study had any role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. Dr Srivastava reports personal fees from Horizon Therapeutics, PLC, AstraZeneca, CVS Caremark, and Tate & Latham (medicolegal consulting). Dr Bonventre is a cofounder of and holds equity in Goldfinch Bio and Autonomous Medical Devices, is a coinventor on KIM-1 patents assigned to Mass General Brigham, has received consulting income related to biomarkers from Biomarin, Aldeyra, PTC, Praxis, and Sarepta, and has received laboratory support from Kantum Pharma. Dr Bonventre's interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Dr Waikar reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, GSK, Mass Medical International, Barron and Budd (vs Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (aka Baim) and grants and personal fees from Allena Pharmaceuticals. The remaining authors declare that they have no relevant financial interests. The authors thank the staff and participants of the Boston Kidney Biopsy Cohort study for their important contributions and invaluable assistance. Received March 18, 2022 as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form April 24, 2022. Funding Information: Funding for the Boston Kidney Biopsy Cohort was provided by the National Institutes of Health (NIH) grant R01DK093574 (Dr Waikar). Dr Schmidt is supported by the American Philosophical Society Daland Fellowship in Clinical Investigation. Dr Srivastava is supported by NIH grant K23DK120811, National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Precision Medicine Project Opportunity Pool grant under U2CDK114886, and core resources from the George M. O{\textquoteright}Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Waikar is also supported by NIH grants UH3DK114915, U01DK085660, U01DK104308, R01DK103784, R01DK093574, and R21DK119751. Dr Bonventre is supported by grants U01DK085660, R01DK072381, and R37DK39773. None of the funders of this study had any role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. ",

year = "2022",

month = aug,

doi = "10.1016/j.xkme.2022.100496",

language = "English (US)",

volume = "4",

journal = "Kidney Medicine",

issn = "2590-0595",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus

T2 - Discordance Between ELISA and Proximity Extension Assay

AU - Schmidt, Insa M.

AU - Colona, Mia R.

AU - Srivastava, Anand

AU - Yu, Guanghao

AU - Sabbisetti, Venkata

AU - Bonventre, Joseph V.

AU - Waikar, Sushrut S.

N1 - Funding Information: Research idea and study design: IMS, SSW; data acquisition: MRC, VS, AS, SSW; data analysis/interpretation: IMS, AS, GY, JVB, SSW; statistical analysis: IMS; supervision or mentorship: SSW, JVB. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Funding for the Boston Kidney Biopsy Cohort was provided by the National Institutes of Health (NIH) grant R01DK093574 (Dr Waikar). Dr Schmidt is supported by the American Philosophical Society Daland Fellowship in Clinical Investigation. Dr Srivastava is supported by NIH grant K23DK120811, National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Precision Medicine Project Opportunity Pool grant under U2CDK114886, and core resources from the George M. O'Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Waikar is also supported by NIH grants UH3DK114915, U01DK085660, U01DK104308, R01DK103784, R01DK093574, and R21DK119751. Dr Bonventre is supported by grants U01DK085660, R01DK072381, and R37DK39773. None of the funders of this study had any role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. Dr Srivastava reports personal fees from Horizon Therapeutics, PLC, AstraZeneca, CVS Caremark, and Tate & Latham (medicolegal consulting). Dr Bonventre is a cofounder of and holds equity in Goldfinch Bio and Autonomous Medical Devices, is a coinventor on KIM-1 patents assigned to Mass General Brigham, has received consulting income related to biomarkers from Biomarin, Aldeyra, PTC, Praxis, and Sarepta, and has received laboratory support from Kantum Pharma. Dr Bonventre's interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Dr Waikar reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, GSK, Mass Medical International, Barron and Budd (vs Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (aka Baim) and grants and personal fees from Allena Pharmaceuticals. The remaining authors declare that they have no relevant financial interests. The authors thank the staff and participants of the Boston Kidney Biopsy Cohort study for their important contributions and invaluable assistance. Received March 18, 2022 as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form April 24, 2022. Funding Information: Funding for the Boston Kidney Biopsy Cohort was provided by the National Institutes of Health (NIH) grant R01DK093574 (Dr Waikar). Dr Schmidt is supported by the American Philosophical Society Daland Fellowship in Clinical Investigation. Dr Srivastava is supported by NIH grant K23DK120811, National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Precision Medicine Project Opportunity Pool grant under U2CDK114886, and core resources from the George M. O’Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. Dr Waikar is also supported by NIH grants UH3DK114915, U01DK085660, U01DK104308, R01DK103784, R01DK093574, and R21DK119751. Dr Bonventre is supported by grants U01DK085660, R01DK072381, and R37DK39773. None of the funders of this study had any role in the study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.

PY - 2022/8

Y1 - 2022/8

KW - ELISA

KW - Olink

KW - plasma kidney injury molecule-1

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=85133375317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133375317&partnerID=8YFLogxK

U2 - 10.1016/j.xkme.2022.100496

DO - 10.1016/j.xkme.2022.100496

M3 - Article

C2 - 36061370

AN - SCOPUS:85133375317

SN - 2590-0595

VL - 4

JO - Kidney Medicine

JF - Kidney Medicine

IS - 8

M1 - 100496

ER -

Plasma Kidney Injury Molecule-1 in Systemic Lupus Erythematosus: Discordance Between ELISA and Proximity Extension Assay

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this